AstraZeneca This fall Earnings: Income And EPS Beat On Greater Most cancers And Respiratory Drug Gross sales, Faces $4.5 Million Potential High-quality In China – AstraZeneca (NASDAQ:AZN)

On Thursday, AstraZeneca Plc AZN reported fourth-quarter gross sales of $14.89 billion, up 18% yr over yr (+19% at fixed foreign money), beating the consensus of $14.29 billion. 

The corporate’s adjusted EPADS reached $1.04, beating the consensus of $1.03. The adjusted EPS was $2.09 (1 ADR = 2 Widespread Shares).

Additionally Learn: AstraZeneca Blames ‘Poisonous’ Local weather As It Walks Away from Over $550 Million UK Vaccine Plant

AstraZeneca’s high enterprise, oncology, increased 27% (up 29% on fixed foreign money) to $6.34 billion.

• Tagrisso gross sales had been up 20% to $1.70 billion (21% at CER), Calquence gross sales elevated 20% to $808 million, Lynparza gross sales elevated 46% (+47%) to $1.44 billion, Imfinzi revenues had been up 16% (+18%) to $1.25 billion, and Enhertu income was up 48% (54% at CER) to $540 million.

Cardiovascular, Renal, and Metabolism (CVRM) gross sales elevated 16% (up 17% at CER) to $3.14 billion.

• Farxiga gross sales had been up 21% (22% at CER) to $1.94 billion, and Lokelma gross sales elevated 35% to $150 million.

Respiratory & Immunology (R&I) gross sales elevated 27% (28% CER) to $2.13 billion.

• Breztri gross sales had been up 29% to $257 million, Saphnelo gross sales elevated 65% to $165 million, Tezspire gross sales had been up 86% (85% at CER) to $213 million, Symbicort revenues jumped 31% (33% CER) to $684 million.

Uncommon Illness drug gross sales elevated by 21% (+22% at CER) to $2.38 billion.

• Ultomiris gross sales had been up 32% (33% at CER) to $1.09 billion, partially offset by a 24% decline in Soliris (22% at CER) to $543 million. Strensiq revenues elevated 38% (37% at CER) to $420 million, and Koselugo gross sales had been up >3x to $265 million.

China: In relation to the unlawful drug importation allegations, in January 2025, AstraZeneca obtained a Discover of Switch to the Prosecutor and an Appraisal Opinion from the Shenzhen Metropolis Customs Workplace concerning suspected unpaid importation taxes amounting to $0.9 million, referred to within the Appraisal Opinion relate to most cancers medicine, Imfinzi and Imjudo.

• A fantastic of 1 and 5 occasions unpaid importation taxes might also be levied if AstraZeneca is discovered liable (amounting to round $0.9 million to $4.5 million). Reuters notes the replace reassures analysts and buyers that the enterprise impression could be minor.
• China gross sales fell 1% on a reported foundation to $1.36 billion (-3% at CER).

Steering: For fiscal yr 2025, AstraZeneca forecasts complete income to extend by a excessive single-digit proportion and core EPS to extend by a low double-digit proportion.

Value Motion: AZN inventory is up 4.43% at $74.08 throughout the premarket session on final examine Thursday.

Learn Subsequent:

Picture by Robert Manner by way of Shutterstock